A recent randomised clinical trial suggests immunomodulators reduce arterial inflammation, and thereby cardiovascular (CV) risk, but shows no significant benefit to TNF inhibitors over triple therapy in patients with rheumatoid arthritis (RA).
Gender Differences in axSpA In abstract 1614, Dr. Poddubnyy presents the results of the PROOF study which assessed the
Tweet Content
Gender Differences in axSpA
In abstract 1614, Dr. Poddubnyy presents the results of the PROOF study which assessed the probability of achieving inactive disease or low disease activity among males and females who were recently diagnosed with axSpA.
https://t.co/DL2TDgXJnG https://t.co/XSQxWWnQgD
Links